College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Republic of Korea.
College of Pharmacy, Yeungnam University, Gyeongsan, Gyeongbuk, Republic of Korea.
PLoS One. 2023 Jun 16;18(6):e0287382. doi: 10.1371/journal.pone.0287382. eCollection 2023.
Despite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study was to evaluate drug-drug interactions between docetaxel and coadministered medicines in patients with breast cancer a claims database. The Health Insurance Review and Assessment Service (HIRA) database (2017 to 2019) was used in this study. We evaluated the risk of neutropenia (defined using receipt of granulocyte colony-stimulating factor (G-CSF) prescriptions) under docetaxel administration or the coadministration of docetaxel and an interacting anticancer drug (predefined based on approval information obtained from the Korean Ministry of Food and Drug Safety and the Lexicomp electronic database). The propensity score matching method was applied to balance covariates in the case (patients with G-CSF prescriptions) and control (patients without G-CSF prescriptions) groups. We identified 947 female patients with breast cancer prescribed with docetaxel and excluded 321 patients based on inclusion criteria. Of the remaining 626 patients, 280 were assigned to the case group and 346 to the control group. Predefined drugs were coadministered to 71 (11.3%) patients during the 7-day period before and after the administration of docetaxel. Adjusted odds ratios (ORs) calculated using the logistic regression model applied to the propensity score matching showed no significant difference between the administration of docetaxel alone and docetaxel coadministration (adjusted OR, 2.010; 95% confidence interval, 0.906, 4.459). In conclusion, we suggest that coadministration of docetaxel and a predefined interacting drug are not associated with G-CSF prescription.
尽管靶向抗癌药物和免疫疗法的使用有所增加，但多西紫杉醇等细胞毒性抗癌药物在临床上仍发挥着重要作用。本研究旨在评估乳腺癌患者接受多西紫杉醇和合并用药的药物-药物相互作用。本研究使用了健康保险审查和评估服务（HIRA）数据库（2017 年至 2019 年）。我们评估了在接受多西紫杉醇治疗或多西紫杉醇与相互作用的抗癌药物（根据从韩国食品药品安全部和 Lexicomp 电子数据库获得的批准信息预先定义）合并用药下中性粒细胞减少症（根据接受粒细胞集落刺激因子（G-CSF）处方定义）的风险。倾向评分匹配法用于平衡病例组（接受 G-CSF 处方的患者）和对照组（未接受 G-CSF 处方的患者）的协变量。我们确定了 947 名接受多西紫杉醇治疗的女性乳腺癌患者，并根据纳入标准排除了 321 名患者。在剩余的 626 名患者中，280 名被分配到病例组，346 名被分配到对照组。在多西紫杉醇给药前 7 天和后 7 天期间，有 71 名（11.3%）患者同时给予了预先定义的药物。使用倾向评分匹配的逻辑回归模型计算的调整后比值比（OR）显示，多西紫杉醇单独给药与多西紫杉醇合并给药之间没有显著差异（调整后 OR，2.010；95%置信区间，0.906，4.459）。总之，我们认为多西紫杉醇与预先定义的相互作用药物合并用药与 G-CSF 处方无关。
